Bone Biologics (OTC:BBLG – Get Rating) and Align Technology (NASDAQ:ALGN – Get Rating) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Valuation & Earnings
This table compares Bone Biologics and Align Technology's revenue, earnings per share (EPS) and valuation.
Get Bone Biologics alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bone Biologics | N/A | N/A | -$1.61 million | N/A | N/A |
| Align Technology | $3.95 billion | 4.02 | $772.02 million | $6.47 | 31.48 |
Align Technology has higher revenue and earnings than Bone Biologics.
Volatility & Risk
Bone Biologics has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.Profitability
This table compares Bone Biologics and Align Technology's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bone Biologics | N/A | 7,587.33% | 7,258.20% |
| Align Technology | 13.22% | 14.39% | 8.89% |
Analyst Ratings
This is a summary of recent recommendations for Bone Biologics and Align Technology, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bone Biologics | 0 | 0 | 1 | 0 | 3.00 |
| Align Technology | 1 | 0 | 7 | 0 | 2.75 |
Bone Biologics currently has a consensus target price of $2.25, suggesting a potential upside of 971.43%. Align Technology has a consensus target price of $298.00, suggesting a potential upside of 46.32%. Given Bone Biologics' stronger consensus rating and higher probable upside, research analysts plainly believe Bone Biologics is more favorable than Align Technology.
Insider and Institutional Ownership
7.6% of Bone Biologics shares are owned by institutional investors. Comparatively, 84.9% of Align Technology shares are owned by institutional investors. 71.5% of Bone Biologics shares are owned by insiders. Comparatively, 0.6% of Align Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Align Technology beats Bone Biologics on 6 of the 11 factors compared between the two stocks.
About Bone Biologics
(Get Rating)
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
About Align Technology
(Get Rating)
Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.